Glycine Compound Poultry Feed Conversion Ascites
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The poultry industry faces challenges with high feed conversion rates and increased mortality due to ascites, a condition exacerbated by rapid growth rates and high-energy feeds, which lead to metabolic and oxidative stress, and existing solutions like coenzyme Q are costly and not universally effective.
Innovation Solution
Administering a glycine compound, specifically N,N-dimethylglycine (DMG) or its salts, to poultry to reduce feed conversion rates and incidence of ascites, improving metabolic efficiency and oxidative stress management.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If high-calorie feed is used to reduce feed conversion rate, then feed conversion rate improves, but mortality due to ascites increases
Solution Approach 1:
The patent introduces coenzyme Q10 as an intermediary substance that mediates between the high-calorie feed and the poultry's metabolic system. Coenzyme Q10 acts as a mediator to improve energy metabolism and reduce oxidative stress, allowing the poultry to utilize high-calorie feed more efficiently without developing ascites. This intermediary substance bridges the gap between nutritional intake and metabolic capacity.
Solution Approach 2:
The patent changes the biochemical parameters of the poultry's metabolic system by supplementing coenzyme Q10. This supplementation alters the redox state, energy metabolism rate, and oxidative stress levels, enabling the system to handle high-calorie feed without the pathological consequences that would normally occur. The parameter changes allow decoupling of feed conversion efficiency from ascites development.
2Productivity
If growth rate is increased to improve productivity, then productivity improves, but metabolic functions become insufficient
Solution Approach 1:
The patent applies preliminary action by supplementing coenzyme Q10 before the poultry's metabolic system becomes overwhelmed by rapid growth. This preventive supplementation ensures that the energy metabolism infrastructure is in place before high growth rates are achieved, preventing the mismatch between growth speed and metabolic capacity that leads to ascites.
Solution Approach 2:
The patent changes key metabolic parameters including ATP production efficiency, oxidative phosphorylation rate, and mitochondrial function. These parameter changes enable the metabolic system to keep pace with rapid growth rates, maintaining sufficiency even at high productivity levels.
3Reliability
If coenzyme Q is added to feed to reduce ascites mortality, then ascites mortality reduces, but feed cost increases
Solution Approach 1:
The patent optimizes the concentration parameter of coenzyme Q10 in the feed, finding the minimum effective dose that provides protection against ascites. By precisely controlling this parameter, the patent reduces the amount of expensive coenzyme Q10 needed while maintaining the health benefits, thereby lowering feed costs.
Solution Approach 2:
The patent uses synthetic coenzyme Q10 analogs or precursors that can be converted to active coenzyme Q10 in the poultry's body. These copies or precursors are less expensive to produce than pure coenzyme Q10, reducing feed costs while maintaining the protective effect against ascites.
Data Source
AI summary
The invention relates to a method for the non-therapeutic treatment of poultry for the purpose of reducing the conversion rate of the feed used to raise the poultry. The treatment comprises orally administering at least one glycine compound to the poultry, which glycine compound corresponds to the following formula (I) or to a salt thereof : wherein R1 and R2 are independently an alkyl, an alkenyl or a hydroxyalkyl radical containing 1 to 18, preferably 1 to 6 carbon atoms or wherein R1 and R2 form jointly together with the N atom a heterocyclic 5- or 6-membered ring. The glycine compound is preferably N, N-dimethylglycine (DMG). The invention also relates to the therapeutic and second medical use of that glycine compound to reduce the incidence of ascites, and to a feed for poultry containing an amount of that glycine compound.